Melanom

60 Years of Data Reveal US Melanoma Epidemic

Survival 81% at 1 Year With MK-3475 in Melanoma

There is an overall survival rate of 81% at 1 year in patients with advanced and unresectable melanoma treated with the experimental immunotherapy MK-3475 (Merck), according to a Kaplan–Meier estimate from a phase 1 trial.
Related articlesInterim Data to Be Presented for MK-3475, Merck & Co., Inc.???s Investigational Anti-PD-1 Immunotherapy, in Patients with Advanced MelanomaMerck Scores in Investigational Melanoma Study ResultsMerck updates MK-3475 data in MelanomaMerck's immunotherapy cancer treatment drug gets good patient response

čtěte zde na stránkách MEDICAL TRIBUNE CZ

Related articles
Bristol-Myers Squibb Announces Phase 1 Results from First Trial Combining Immune Checkpoint InhibitoNivolumab Tested For Safety In Kidney CancerSafety of Nivolumab in Kidney Cancer Tested By Dartmouth ResearchersNivolumab plus ipilimumab shows promise for metastatic melanomaThis Pharma Is Trading Like a Biotech

Basal-cell carcinoma (Photo credit: Wikipedia)Vitamin D level and Basal cell carcinoma, squamous cell carcinoma, and melanoma risk | DocGuide

...  Pols et al. observed that baseline 25-hydroxyvitamin D (25OHD) levels above 75 nmol/L were associated with an increased incidence of basal cell carcinoma and melanoma, and a nonstatistically significant decreased incidence of squamous cell carcinoma...

Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab - Weber - 2013 - Cancer - Wiley Online Library
Related articlesImproved survival with ipilimumab in metastatic melanomaUpdate on malignant melanoma therapies